Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals
J Parrino, LH McCurdy, BD Larkin, IJ Gordon… - Vaccine, 2007 - Elsevier
J Parrino, LH McCurdy, BD Larkin, IJ Gordon, SE Rucker, ME Enama, RA Koup, M Roederer…
Vaccine, 2007•ElsevierModified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax® in vaccinia-
naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or
placebo followed by Dryvax® challenge at 3 months. Two or more doses of MVA prior to
Dryvax® reduced severity of lesion formation, decreased magnitude and duration of viral
shedding, and augmented post-Dryvax® vaccinia-specific CD8+ T cell responses and
extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe …
naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or
placebo followed by Dryvax® challenge at 3 months. Two or more doses of MVA prior to
Dryvax® reduced severity of lesion formation, decreased magnitude and duration of viral
shedding, and augmented post-Dryvax® vaccinia-specific CD8+ T cell responses and
extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe …
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax® in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax® challenge at 3 months. Two or more doses of MVA prior to Dryvax® reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax® vaccinia-specific CD8+ T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax® vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.
Elsevier